Silverarc Capital Management’s Verona Pharma VRNA Stock Holding History

Silverarc Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-358,297	Closed	-$33.9M	–	96
2025 Q2	$33.9M	Sell	358,297 -187,575	-34%	-$13.9M	6.25%	3
2025 Q1	$34.7M	Buy	545,872 +29,858	+6%	+$1.79M	7.09%	1
2024 Q4	$24M	Buy	516,014 +167,148	+48%	+$6.28M	5.24%	4
2024 Q3	$10M	Buy	348,866 +44,233	+15%	+$1.09M	2.25%	15
2024 Q2	$4.4M	Buy	304,633 +167,919	+123%	+$2.45M	1.04%	33
2024 Q1	$2.2M	Buy	+136,714	New	+$2.36M	0.61%	48

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Silverarc Capital Management's VRNA Position: Q3 2025 in Review

Silverarc Capital Management sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 358,297 shares — an estimated $33.9M sold.

Silverarc Capital Management first reported a position in VRNA in Q1 2024 and held it in 6 quarters. The position peaked at $34.7M in Q1 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Silverarc Capital Management reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Silverarc Capital Management sold 358,297 Verona Pharma shares in Q3 2025, an estimated $33.9M.
Silverarc Capital Management first reported a position in Verona Pharma in Q1 2024 and held it in 6 quarters.
Silverarc Capital Management's Verona Pharma position peaked at $34.7M in Q1 2025.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.